This strategy allows clinicians to select a harm to benefit ratio that is most appropriate for their clinical practice, and allows more accurate patient selection than when testing all or no patients, or patients with pre‐operative anaemia (Hb < 130 g/L). This evidence concerns the gene GSTM1 and anemia.